Moderna News and Biotech Innovation Updates
Moderna Inc. (NASDAQ: MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. Best known for its COVID-19 vaccine, Moderna leverages mRNA technology to develop treatments for infectious diseases, cancer, autoimmune conditions, and rare genetic disorders. Its modular platform enables rapid drug development and scalable manufacturing, positioning the company at the forefront of biotech innovation. Headquartered in Cambridge, Massachusetts, Moderna continues to expand its clinical pipeline and forge strategic partnerships with governments and research institutions worldwide. The company's long-term mission is to transform medicine by unlocking the potential of mRNA to treat and prevent a wide range of diseases.
73.8
5.9700
7.48 %
At close
07/08
USD
Daily range
73.57
77.34
77.34
Weekly range
73.57
85.60
85.60
Moderna shares drop around 6.5% after overbought signals and regulatory news
Moderna Inc (MRNA) fell 6.59% as selling pressure followed a recent run of positive news, most notably progress toward regulatory review of its mRNA influenza vaccine and anticipation ahead of its ...
Why is Moderna stock down today?
Moderna (MRNA) stock is trading at $78.38, posting a decline of 4.18% on the day. The stock sits below its short-term moving averages and above key medium- and long-term ...
Moderna stock price outlook: Is the rally overextended?
Moderna shares continue to rally, gaining more than 38% since June 26, as positive momentum following the company's updated drug pipeline continues to support investor sentiment.Since our ...
Can Moderna extend its 43% rally?
June has been one of Moderna's strongest months in recent years. However, after such a powerful rally, the stock's next move will likely depend on fresh fundamental catalysts.There have been ...
Moderna stock consolidates above key moving averages amid focus on three-horizon strategy
Moderna shared its plans for the next decade and beyond at its Science Day event.CEO Stéphane Bancel published a blog post outlining Moderna's three-horizon strategy. The plan focuses on current ...
Moderna rallies on vaccine progress as investors await revenue growth
Moderna remains one of the leaders in the biotechnology sector thanks to its progress in developing new vaccines. However, after gaining more than 46% in just two weeks, investors are beginning ...
Moderna surges after FDA backing, but profit-taking risks emerge
Moderna shares posted their strongest weekly performance in more than four years following the FDA's decision regarding its influenza vaccine.The main catalyst behind Moderna's rally was ...
What triggered Moderna shares' latest price surge
Moderna Inc (MRNA) is currently trading at $63.75 after a daily gain of 3.16%. The stock remains well above its 20-day ($49.08), 50-day ($49.96), and 200-day ($39.02) moving averages, signaling a ...
Why is Moderna stock up today?
Moderna Inc (MRNA) is trading at $58.58, up $3.18 or 5.74% for the day, positioning itself significantly above the 20-day ($48.28), 50-day ($49.73), and 200-day ($38.83) moving averages. This ...
FDA boost lifts Moderna shares: Can MRNA extend rally?
Moderna shares moved higher after the FDA released briefing documents related to the company's mFlu influenza vaccine, which investors interpreted as a positive signal for the potential approval ...
Buying pressure lifts Moderna stock higher in today's trading
Moderna Inc. (MRNA) is trading decisively above its key short-term, medium-term, and long-term moving averages, with the price ($55.76) above the MA-20 ($47.91), MA-50 ($49.60), and MA-200 ...
What is behind Moderna stock's recent gain in value today
Moderna Inc. (MRNA) is trading at $50.67, up 2.07% today. The stock sits above its 20-day ($47.77), 50-day ($49.54), and 200-day ($38.42) moving averages, highlighting persistent bullish trends ...
Moderna eyes breakout as investors focus on its next growth drivers
Moderna shares continue to recover after a challenging period between 2023 and 2025. The key question now is whether the stock can break out of its current consolidation range in the near ...
Why is Moderna stock down today?
Moderna Inc. (MRNA) is trading at $46.42, below the 20-day ($48.17) and 50-day ($49.61) moving averages, reflecting persistent short- and medium-term selling pressure, while remaining well above ...
Moderna edges higher to $47.60 after MHRA approves mRNA-4194 Lynch syndrome trial, moderna_tx says
Moderna received authorization from the UK’s Medicines and Healthcare products Regulatory Agency for its Phase 1/2 clinical study evaluating mRNA-4194.The investigational mRNA-based vaccine is ...
Moderna edges higher to $47.60 as Oxford cancer vaccine trial gains UK authorization, moderna_tx announces
Moderna said it has received Medicines and Healthcare products Regulatory Agency (MHRA) authorization in the UK for a Phase 1/2 study of mRNA-4194, its investigational cancer vaccine for Lynch ...
Why is Moderna stock up today?
Moderna Inc. (MRNA) is currently trading near $47.23, below both the 20-day ($48.56) and 50-day ($49.93) moving averages, but well above the 200-day average at $37.67. This setup points to ...
Buying pressure lifts Moderna stock higher in today's trading
Moderna Inc (MRNA) is currently trading at $48.67, registering a daily gain of 2.31%. The stock sits just above its 20-day moving average ($48.55) and remains below the 50-day moving average ...
Why is Moderna stock down today?
Moderna Inc (MRNA) is currently trading at $46.53, down 2.27% on the day. The asset remains below its 20-day ($48.45) and 50-day ($50.40) moving averages, indicating continued short- and ...
What is behind Moderna stock's recent gain in value today
Moderna Inc (MRNA) is trading at $48.17 after gaining 2.42% on the day. The stock currently sits just below its 20-day and 50-day simple moving averages ($48.43 and $50.51, respectively), but ...
Selling pressure pushes Moderna stock lower in today's trading
Moderna Inc. (MRNA) is currently trading at $46.96, down 2.42% for the day. The price remains below its MA-20 ($48.99) and MA-50 ($50.93), yet comfortably above its MA-200 ($36.85), indicating ...
